Edition:
United Kingdom

People: Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

45.61USD
15 Jul 2019
Change (% chg)

-- (--)
Prev Close
$45.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
203,828
52-wk High
$60.98
52-wk Low
$36.19

Braunstein, Scott 

Dr. Scott Braunstein, M.D. is an Independent Director of the Company. He is an Operating Partner at Aisling Capital, a private investment firm, and currently serves as Senior Vice President of Strategy and Corporate Development at Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management from 2014 through 2015. Previously, from 2002 to 2014, he worked in various positions at JP Morgan Asset Management, a division of JPMorgan Chase & Co. (NYSE: JPM), most recently as a managing director, senior portfolio manager for the JPM Global Healthcare Fund, and the JPM asset global equity analyst for the U.S. pharmaceutical and biotechnology industry. Prior to that, he worked at Deutsche Bank from 2000 to 2002 as a health care equity sales specialist and as vice president of operations at Defined Healthcare from 1999 to 2000. He is board certified in Internal Medicine, having completed his residency at the New York Hospital-Cornell Medical Center, and achieved the title of assistant clinical professor of medicine at Columbia University Medical Center. Dr. Braunstein earned his bachelor degree from Cornell University and his medical degree from the Albert Einstein College of Medicine at Yeshiva University.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 343,846
Long-Term Incentive Plans, USD --
All Other, USD 52,278
Fiscal Year Total, USD 396,124

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --